Status: Recruiting
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Participants needed: 45
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: May 6, 2026Locations: 16
Eligibility criteria
Age ≥ 6 at the time of informed consent [+31]
Prior Therapy: Has received selinexor or another XPO1 inhibitor previously. [+5]